Pharma

Your Article Summary

See Latest Articles

Genzyme’s Alemtuzumab for Multiple Sclerosis Shows Durable Treatment Benefit in Review of Four-Year Phase 2 Trial Data
Genzyme, 09/14/09

Genzyme Corporation reported that four–year follow–up data from its completed Phase 2 multiple sclerosis trial continued to show durable reductions in relapse rate and sustained accumulation of disability three years after the majority of patients received their last course of the investigational compound alemtuzumab. The CAMMS223 Phase 2 trial compared alemtuzumab to an approved MS therapy Rebif® in early, relapsing–remitting multiple sclerosis patients who had received no prior therapy.

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid Tumors
Journal of Clinical Oncology, 12/09/09

The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury
Trials, 12/09/09

Umbilical vein oxytocin for the treatment of retained placenta (Release Study): a double-blind, randomised controlled trial
The Lancet - Early Online Publication, 12/09/09

 See all of Drug Trials